Clinical Trial Detail

NCT ID NCT03906071
Title Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Mirati Therapeutics Inc.
Indications

lung non-squamous non-small cell carcinoma

Therapies

Docetaxel

MGCD516 + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST